Read by QxMD icon Read


Diego Novick, William Montgomery, Tamas Treuer, Maria Victoria Moneta, Josep Maria Haro
This study assessed the comparative effectiveness of antipsychotics in the treatment of patients with schizophrenia presenting with prominent negative symptoms and no-to-mild positive symptoms. Data were taken from a 3-year prospective, international, observational study (n=17 384). This post-hoc study focused on 3 712 patients who started antipsychotic monotherapy and had moderate-to-severe negative symptoms and no-to-mild positive symptoms (Clinical Global Impression-Severity Scale [GGI-SCH]). Patients were classified into 3 treatment cohorts: olanzapine, other atypicals and typicals...
February 16, 2017: Pharmacopsychiatry
Jürgen Dinger, Patricia Hinner, Jörg Reichert, Mario Rüdiger
Methamphetamine abuse during pregnancy represents an emerging health care problem. The consequences are not only of relevance to the pregnant women, but also their unborn child. It is associated with an increased risk of preeclampsia and hypertension, fetal demise, preterm delivery, and intrauterine growth restriction. The deleterious effects of prenatal methamphetamine exposure on the developing fetal brain may lead to long-term neuro-developmental and behavioral problems.Given the current evidence, abuse of methamphetamine during pregnancy must be of utmost concern to health care professionals and to policy-makers...
February 8, 2017: Pharmacopsychiatry
R Colle, D de Larminat, S Rotenberg, F Hozer, P Hardy, C Verstuyft, B Fève, E Corruble
Introduction: Selective agonists of the nuclear transcription factor peroxisome proliferator-activated receptor-gamma (PPAR-γ) are used for the treatment of type 2 diabetes. We reviewed their efficacy and safety for the treatment of major depression and the association of their potential antidepressant effects with changes in biomarkers of metabolism and inflammation. Methods: From 8 studies, 4 open-label trials, and 4 randomized controlled trials (RCT) (3 vs. placebo and 1 vs. metformin), 448 patients with major depression were included, of which 209 patients received PPAR-γ agonists (pioglitazone or rosiglitazone) for 6-12 weeks, either alone or in add-on therapy to conventional treatments...
December 15, 2016: Pharmacopsychiatry
(no author information available yet)
No abstract text is available yet for this article.
January 2017: Pharmacopsychiatry
(no author information available yet)
No abstract text is available yet for this article.
January 2017: Pharmacopsychiatry
Hiroyuki Uchida, Wolfgang Fleischhacker, Georg Juckel, Gerhard Gründer, Michael Bauer
No abstract text is available yet for this article.
January 2017: Pharmacopsychiatry
Yoon Phaik Ooi, Shih-Jen Weng, Joe Kossowsky, Heike Gerger, Min Sung
Aim: Oxytocin presents an exciting potential to target the core symptoms of autism spectrum disorder (ASD) pharmacologically in an easily administered, cost-effective form with possibly minimal adverse effects. But, there are still major gaps in this area of research. This paper reviewed randomized controlled trials (RCTs) examining the effects of oxytocin administration on social cognition and restricted, repetitive behaviors in individuals with an ASD. Method: Electronic literature searches were conducted from PsycINFO, PubMed, Web of Knowledge, and EMBASE for RCTs published through June 2015...
January 2017: Pharmacopsychiatry
Michael Deuschle, Andreas Böhringer, Andreas Meyer-Lindenberg, Alexander Sartorius
Introduction: Serotonin syndrome is a potentially life-threatening condition with delirium, vegetative and neuromuscular symptoms as well as neural hyperexcitability. The main causes are combinations of serotonergic drugs, excessive dosages of serotonergic agents or the recreational use of certain drugs. Methods and Results: We report a case of a patient who started developing serotonin syndrome after a cumulative dose of only 900 mg lithium carbonate given in temporal association with electroconvulsive therapy (ECT)...
January 2017: Pharmacopsychiatry
F J Zamora Rodríguez, C Benítez Vega, M R Sánchez-Waisen Hernández, J A Guisado Macías, F J Vaz Leal
Introduction: Paliperidone palmitate treatment of schizophrenia or schizoaffective disorder is effective and well tolerated, but there is almost no data on its safety during pregnancy. Case report: An analysis is made of the safety and tolerability of paliperidone palmitate treatment throughout the gestation period in a 34-year-old patient diagnosed with schizoaffective disorder. Discussion: Paliperidone palmitate treatment throughout the gestation period was safe and well tolerated by both mother and foetus, there being no malformations or other perinatal complications in the newborn to date...
January 2017: Pharmacopsychiatry
Federico Manuel Daray, Demián Rodante, Laura G Carosella, María Elena Silva, Melina Martínez, María V Fernández Busch, Diego F Faccone, Rodolfo P Rothlin, Paulo C Maffía
Introduction: The HTR2C gene is an important candidate in pharmacogenetic studies of antipsychotic-induced weight gain (AIWG). However, inconsistent results have been obtained. The present study investigated the association between -759C>T, functional polymorphism of the HTR2C receptor, and AIWG. Methods: A prospective cohort of 48 female inpatients with schizophrenia and related illness treated according to normal clinical practice with second generation antipsychotics (SGAs) risperidone, clozapine, quetiapine, and olanzapine were evaluated...
January 2017: Pharmacopsychiatry
Artur Pałasz, Ewa Rojczyk, Aleksandra Suszka-Świtek, Ryszard Wiaderkiewicz
Introduction: Kisspeptin has a multidirectional neuroendocrinal activity. It is especially considered to be a central regulator of reproductive function. Numerous data proved that neuroleptic administration may affect the peptidergic signaling in the various brain structures. However, there is no information concerning the relationship between treatment with neuroleptics and brain kisspeptin mRNA expression. Methods: We assessed the kisspeptin mRNA level in the hypothalamus and hippocampus of rats shortly and chronically (28 days) treated with haloperidol, chlorpromazine, and olanzapine using a quantitative Real-Time PCR method...
January 2017: Pharmacopsychiatry
Nikvarz Nikvarz, Javad Alaghband-Rad, Mehdi Tehrani-Doost, Abbas Alimadadi, Padideh Ghaeli
Introduction: This study was aimed to compare the efficacy and side effects of memantine, an antagonist of the NMDA receptor of glutamate, with risperidone given the fact that glutamate has been noted for its possible effects in the pathogenesis of autism. Risperidone, an atypical antipsychotic, has been approved by FDA for the management of irritability associated with autism. Methods: 30 children, aged 4-17 years, entered an 8-week, randomized trial. Patients were randomly assigned to receive either risperidone or memantine...
January 2017: Pharmacopsychiatry
Stefan Roepke, Heidi Danker-Hopfe, Dimitris Repantis, Behnoush Behnia, Florian Bernard, Marie-Luise Hansen, Christian Otte
Objective: Centrally active α-1-adrenergic-receptor antagonists such as prazosin are effective in the treatment of nightmares in patients with posttraumatic stress disorder (PTSD). A pharmacological alternative is doxazosin, which has a longer half-life and fewer side effects. However, doxazosin is currently being used without solid empirical evidence. Furthermore, no study so far has assessed the effects of α-1-antagonists on nightmares in patients with borderline personality disorder (BPD). We retrospectively assessed the effectiveness of doxazosin on nightmares in PTSD and BPD...
January 2017: Pharmacopsychiatry
G Juckel
The editors of Pharmacopsychiatry have decided in 2016 to prepare special issues regularly in order provide our readers volumes of the journal with a thematic focus 1. The first such special issue is dedicated to the field of child and adolescent psychopharmacology. Many young patients are treated with psychotherapeutic, but also pharmacotherapeutic, methods worldwide. Most of our psychopharmacological agents are not approved by the federal institutions for persons under 18 years old. However, severe mental illnesses like schizophrenia, depression, anxiety, ADHD, and bipolar disorder frequently require pharmacological treatments in children and adolescents...
November 2016: Pharmacopsychiatry
B Vitiello
No abstract text is available yet for this article.
November 2016: Pharmacopsychiatry
M Lambert, V Niehaus, C Correll
This review aims to describe the importance of i) detecting individuals at clinical high-risk for psychosis (schizophrenia) or bipolar disorder, especially in children and adolescents, in order to enable early intervention, and ii) evaluating different intervention strategies, especially pharmacotherapy, during the subsyndromal or "prodromal" stages of these severe and often debilitating disorders. The different approaches regarding the psychotic and bipolar clinical high-risk state are discussed, including reasons and evidence for early (pharmacological) intervention and risks of treatment vs...
November 2016: Pharmacopsychiatry
M Kölch, P L Plener
Pharmacotherapeutic interventions are available for most psychiatric disorders in children. Evidence for these interventions varies, depending on the targeted disorders. For attention-deficit/hyperactivity disorder, a sound database on efficacy and safety of medication exists. For other common disorders or psychopathological phenomena like disruptive behavior, anxiety disorders, depressive disorders, or autism, data on efficacy and safety are much scarcer. This selective review aims to provide an overview about current psychopharmacological interventions in child and adolescent psychiatry...
November 2016: Pharmacopsychiatry
E Trinczek, M Heinzel-Gutenbrunner, M Haberhausen, C J Bachmann
Introduction: Early-onset schizophrenia (EOS) has a poor prognosis and is difficult to treat, which often leads to the initiation of clozapine treatment. Studies in adults have shown that the initiation of clozapine treatment is often delayed. There is a lack of studies concerning the initiation of clozapine in children and adolescents with EOS. The aim of this study was to investigate the time span from first EOS-related psychiatric hospitalization to clozapine initiation. Methods: We retrospectively studied a consecutive cohort of children and adolescents with EOS and first-time clozapine prescriptions from a tertiary care child and adolescent psychiatric center in Germany...
November 2016: Pharmacopsychiatry
M Holtmann, B G Schimmelmann
No abstract text is available yet for this article.
November 2016: Pharmacopsychiatry
S Langgartner, W Strube, T Oviedo, M Hansbauer, S Karch, S Wirth, P Falkai, A Hasan
No abstract text is available yet for this article.
November 2016: Pharmacopsychiatry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"